Trial Profile
An International Multicentre, Open-Label First in Human Phase I/II Study to Evaluate the Safety, Tolerability, Biodistribution and Antitumour Activity of 177Lu-3BP-227 for the Treatment of Subjects With Solid Tumours Expressing Neurotensin Receptor 1
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 18 Dec 2023
Price :
$35
*
At a glance
- Drugs Zalsenertant-tetraxetan (Primary)
- Indications Adenocarcinoma; Colorectal cancer; Ewing's sarcoma; Gastric cancer; Gastrointestinal stromal tumours; Head and neck cancer; Pancreatic cancer; Solid tumours; Squamous cell cancer
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Ipsen
- 02 Jun 2021 Status changed from recruiting to discontinued due to agreement to transfer rights for IPN01087 to an external partner, not due to safety concerns
- 21 Mar 2021 This trial has been completed in Belgium, according to European Clinical Trials Database record.
- 23 Feb 2021 Planned End Date changed from 3 Aug 2026 to 3 Aug 2022.